zanubrutinib

{
  "id": "MLC-T-ONC-009459",
  "term": "zanubrutinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with another drug to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain types of non-Hodgkin lymphoma, including follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenström’s macroglobulinemia. It is also being studied in the treatment of other types of cancer. Zanubrutinib blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Brukinsa.",
    "An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival."
  ],
  "synonyms": [
    "Brukinsa",
    "BTK-InhB"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zanubrutinib/"
}